.png)
German (DE) 
English (US) 
Spanish (ES) 
French (FR) 
Hindi (IN) 
Italian (IT) 
Russian (RU) - Today's news
- US
- Politics
- World
- Tech
- Weather
- Climate change
- Health
- Science
- Originals
- Newsletters
- Games
- Health
- Parenting
- Style and beauty
- Horoscopes
- Shopping
- Food
- Travel
- Autos
- Gift ideas
- Buying guides
- My Portfolio
- News
- Markets
- Stocks: Most Actives
- Stocks: Gainers
- Stocks: Losers
- Trending Tickers
- Futures
- World Indices
- US Treasury Bonds Rates
- Currencies
- Crypto
- Top ETFs
- Top Mutual Funds
- Options: Highest Open Interest
- Options: Highest Implied Volatility
- Sectors
- Basic Materials
- Communication Services
- Consumer Cyclical
- Consumer Defensive
- Energy
- Financial Services
- Healthcare
- Industrials
- Real Estate
- Technology
- Utilities
- Private Companies
- Research
- Personal Finance
- Videos
- Watch Now
- Fantasy
- Daily fantasy
- NFL
- NBA
- MLB
- NHL
- College football
- College basketball
- Soccer
- NFL Draft
- Yahoo Sports AM
- Show all
© 2025 All rights reserved.
TipRanks
Sat, Jun 28, 2025, 9:25 AM 1 min read
In This Article:
Wedbush analyst Laura Chico lowered the firm’s price target on Edgewise Therapeutics (EWTX) to $35 from $40 and keeps an Outperform rating on the shares. Edgewise said the FDA has deemed CANYON data insufficient to support an accelerated filing for sevasemten in Becker muscular dystrophy, but the company will explore additional avenues to speed the process, and will seek full approval with GRAND CANYON, the analyst tells investors in a research note. Wedbush still sees several unanswered questions for sevasemten in DMD such as the patient population to be studied, the firm says.
Confident Investing Starts Here:
-
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
-
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EWTX:
Terms and Privacy Policy
Comments